产品
编 号：F749580
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 2171061-85-9
产品详情
生物活性：
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .
体内研究：
Nidanilimab (CAN04; 10 mg/kg; i.p.; 裸 C57Bl/6 小鼠) 增加了两种常用的铂基化疗药物顺铂 (HY-17394)/吉西他滨 (HY-17026) 和卡铂 (HY-17393)/吉西他滨 (HY-17026) 的疗效。Animal Model:Nude C57Bl/6 mice with LU2503 NSCLC PDX model
Dosage:10 mg/kg
Administration:Intraperitoneal injection
Result:Displayed a significantly stronger anti-tumor effect compared to isotype control with chemotherapy.
体外研究：
Nidanilimab (CAN04; 20 μg/mL; 小鼠 MC38 结肠癌细胞) 具有糖工程介导增强的抗体依赖性细胞毒性 (ADCC, EC50Nidanilimab 相关抗体:
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .
体内研究：
Nidanilimab (CAN04; 10 mg/kg; i.p.; 裸 C57Bl/6 小鼠) 增加了两种常用的铂基化疗药物顺铂 (HY-17394)/吉西他滨 (HY-17026) 和卡铂 (HY-17393)/吉西他滨 (HY-17026) 的疗效。Animal Model:Nude C57Bl/6 mice with LU2503 NSCLC PDX model
Dosage:10 mg/kg
Administration:Intraperitoneal injection
Result:Displayed a significantly stronger anti-tumor effect compared to isotype control with chemotherapy.
体外研究：
Nidanilimab (CAN04; 20 μg/mL; 小鼠 MC38 结肠癌细胞) 具有糖工程介导增强的抗体依赖性细胞毒性 (ADCC, EC50Nidanilimab 相关抗体:
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备